<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533113</url>
  </required_header>
  <id_info>
    <org_study_id>ENDECL201804</org_study_id>
    <nct_id>NCT04533113</nct_id>
  </id_info>
  <brief_title>Carious Tissue Selective Removal on Permanent Posterior Teeth.</brief_title>
  <official_title>Carious Tissue Selective Removal on Permanent Posterior Teeth. A Randomized Controlled Clinical Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan Gonzalo Olivieri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitat Internacional de Catalunya</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective randomized controlled study of patients who come to the&#xD;
      University. The aim is to evaluate the success rate of selective removal of carious tissue in&#xD;
      deep lesions of posterior teeth. Three different materials will be used as liners (VitreBond&#xD;
      ™Plus, BioDentine™, and Theracal™ LC). Post-operative pain, clinical, and radiographic&#xD;
      success will be evaluated at one, two, and five-year follow-up. The null hypothesis is that&#xD;
      there will be no statistically significant differences in rates of successful treatment with&#xD;
      the three materials used.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical post-operative pain</measure>
    <time_frame>Immediately post-treatment</time_frame>
    <description>VAS score of patient' level of pain, from no pain to extreme pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical post-operative pain</measure>
    <time_frame>8 hours post-treatment</time_frame>
    <description>VAS score of patient' level of pain, from no pain to extreme pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical post-operative pain</measure>
    <time_frame>24 hours post-treatment</time_frame>
    <description>VAS score of patient' level of pain, from no pain to extreme pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical post-operative pain</measure>
    <time_frame>48 hours post-treatment</time_frame>
    <description>VAS score of patient' level of pain, from no pain to extreme pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical signs or symptoms of pulp or periapical disease</measure>
    <time_frame>1 year</time_frame>
    <description>Absence/presence of clinical signs or symptoms of pulp or periapical disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical signs or symptoms of pulp or periapical disease</measure>
    <time_frame>2 years</time_frame>
    <description>Absence/presence of clinical signs or symptoms of pulp or periapical disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical signs or symptoms of pulp or periapical disease</measure>
    <time_frame>5 years</time_frame>
    <description>Absence/presence of clinical signs or symptoms of pulp or periapical disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic signs of periapical disease</measure>
    <time_frame>1 year</time_frame>
    <description>Absence/presence of radiographic apical periodontitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic signs of periapical disease</measure>
    <time_frame>2 years</time_frame>
    <description>Absence/presence of radiographic apical periodontitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic signs of periapical disease</measure>
    <time_frame>4 years</time_frame>
    <description>Absence/presence of radiographic apical periodontitis</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Dental Caries</condition>
  <condition>Dental Materials</condition>
  <arm_group>
    <arm_group_label>VitreBond LC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VitreBond LC used as a liner after selective carious tissue removal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biodentine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biodentine used as a liner after selective carious tissue removal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Theracal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Theracal used as a liner after selective carious tissue removal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Carious tissue selective removal</intervention_name>
    <description>Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration</description>
    <arm_group_label>Biodentine</arm_group_label>
    <arm_group_label>Theracal</arm_group_label>
    <arm_group_label>VitreBond LC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients that demonstrate understanding of the study and willingness to participate as&#xD;
             evidenced by signing the voluntary informed consent and received a signed and dated&#xD;
             copy of the informed consent form.&#xD;
&#xD;
          -  Understands and is willing to comply with all study procedures and restrictions.&#xD;
&#xD;
          -  Not presence of clinically significant and relevant abnormalities of clinical history&#xD;
             or oral examination.&#xD;
&#xD;
          -  Diagnosis of normal pulp or reversible pulpitis.&#xD;
&#xD;
          -  No presence of periapical periodontitis&#xD;
&#xD;
          -  Posterior teeth&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General: Patients with systemic diseases, diabetes, immunocompromised and pregnant women,&#xD;
        or any clinically significant or relevant oral abnormalities.&#xD;
&#xD;
        Specific: Impossibility of restoration, diagnosis of irreversible pulpitis or necrosis,&#xD;
        preoperative pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitat Internacional de Catalunya</name>
      <address>
        <city>Sant Cugat Del Vallès</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan G. Olivieri, DDS, PhD</last_name>
      <phone>935042000</phone>
      <email>jgolivieri@uic.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universitat Internacional de Catalunya</investigator_affiliation>
    <investigator_full_name>Juan Gonzalo Olivieri</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Dental caries</keyword>
  <keyword>Dental materials</keyword>
  <keyword>Outcome</keyword>
  <keyword>Postoperative Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

